Financial Times: If Covid vaccines stop working, how quickly can drugmakers respond?

Andrey Zarur, CEO of GreenLight Biosciences, spoke to the Financial Times about how regulators will respond if Covid-19 vaccines stop working.

Andrey Zarur, CEO of GreenLight Biosciences, spoke to the Financial Times about how regulators will respond if Covid-19 vaccines stop working. Extracts from the article are below:

But Andrey Zarur, chief executive of GreenLight Biosciences, which is developing an mRNA Covid-19 vaccine, said the FDA had informed the company that it would not need to redo safety trials if all of the vaccine ingredients were the same and only the viral sequence was changed.  “We have assurances from the FDA that if we proceed with one strain of DNA, and then we change it, then we would not need to start with early stage clinical trials at all,” he added. The FDA said it had already “given thought to developing a potential pathway” for changes to Covid-19 vaccines and treatments.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.